论文部分内容阅读
目的研究急性髓细胞白血病(AML)患者治疗前后的血清乳酸脱氢酶(LDH)和白细胞介素Ⅱ(IL-Ⅱ)的变化及临床意义。方法选择30例急性髓细胞白血病患者检测化疗前后LD(H酶法)及IL-Ⅱ(ELISA法)水平,并与正常人对照进行分析。结果急性髓细胞白血病初治组LDH显著高于缓解组及正常对照组,IL-Ⅱ则显著低于正常对照组,IL-Ⅱ浓度在化疗后有显著回升。结论LDH和IL-Ⅱ联合检测对于急性髓细胞白血病监测病情,疗效判断和指导治疗有参考价值。
Objective To study the changes and clinical significance of serum lactate dehydrogenase (LDH) and interleukin Ⅱ (IL-Ⅱ) in patients with acute myeloid leukemia (AML) before and after treatment. Methods Thirty patients with acute myeloid leukemia were tested for LD (H enzyme) and IL-Ⅱ (ELISA) before and after chemotherapy, and compared with normal controls. Results The LDH of the newly diagnosed acute myeloid leukemia group was significantly higher than that of the remission group and the normal control group, while IL-Ⅱ was significantly lower than that of the normal control group. The concentration of IL-Ⅱ increased significantly after chemotherapy. Conclusions The combined detection of LDH and IL-Ⅱ has reference value for the monitoring of acute myeloid leukemia, judging the curative effect and guiding treatment.